SCHEMBL1684262

SCHEMBL1684262

O=P(O)(O)CCOP(=O)(O)O

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LPAR3 Q9UBY5 8/20 0.46
LPAR2 Q9HBW0 6/20 0.46
LPAR1 Q92633 4/20 0.46
TYMS P04818 1/20 0.45
ALDH1A1 P00352 1/20 0.41
LMNA P02545 1/20 0.38
CYP3A4 P08684 1/20 0.38
NFKB1 P19838 1/20 0.38
BLM P54132 1/20 0.38
PMP22 Q01453 1/20 0.38
CSNK2A2 P19784 1/20 0.37
CSNK2B P67870 1/20 0.37
CSNK2A1 P68400 1/20 0.37
CSNK2A3 Q8NEV1 1/20 0.37
TPI1 P60174 2/20 0.37
PGK1 P00558 1/20 0.36
PGK2 P07205 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL596972 0.83 TYMS (0.55) LPAR3LPAR2LPAR1TYMSLMNA
SCHEMBL811703 0.81 LPAR3 (0.55) LPAR3LPAR2LPAR1BLMCSNK2A2
SCHEMBL4534560 0.79 LPAR3 (0.61) LPAR3LPAR2LPAR1TYMSLMNA
SCHEMBL4531985 0.79 LPAR3 (0.61) LPAR3LPAR2LPAR1TYMSLMNA
SCHEMBL4521703 0.79 LPAR3 (0.61) LPAR3LPAR2LPAR1TYMSLMNA
SCHEMBL4533913 0.79 LPAR3 (0.61) LPAR3LPAR2LPAR1TYMSLMNA
SCHEMBL4524705 0.79 LPAR3 (0.61) LPAR3LPAR2LPAR1TYMSLMNA
SCHEMBL4528434 0.79 LPAR3 (0.61) LPAR3LPAR2LPAR1TYMSLMNA
SCHEMBL4530294 0.79 LPAR3 (0.61) LPAR3LPAR2LPAR1TYMSLMNA
SCHEMBL4524581 0.79 LPAR3 (0.61) LPAR3LPAR2LPAR1TYMSLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1654204-B1 COLLOIDAL HYDROXIDE AQUEOUS SUSPENSION OF AT LEAST ONE TRANSITION ELEMENT SERVING TO REDUCE CHROME IN CEMENT CHRYSO (FR) 2009-03-04 EP claimed
WO-2015119528-A1 INHIBITOR OF METAL CORROSION AND SCALING РОМАНОВА, Нелли Евгеньевна 2015-08-13 WO disclosed
WO-2011041512-A2 COMPOSITIONS AND METHODS FOR TREATING MLV-INFECTION, AND PREVENTING AND TREATING MLV-INITIATED DISEASES EMORY UNIVERSITY (US) 2011-04-07 WO disclosed
US-20090029939-A1 Pre-organized tricyclic integrase inhibitor compounds GILEAD SCIENCES, INC. 2009-01-29 US disclosed
US-20070287644-A1 LUBRICATING OIL COMPOSITION SHELL OIL COMPANY 2007-12-13 US disclosed
EP-1860175-A2 Lubricating oil composition SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 2007-11-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090029939-A1 Pre-organized tricyclic integrase inhibitor compounds MUS81, CDKL4, INTS6 LPAR3 2821/4885LPAR2 3445/4885LPAR1 2985/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.